Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 14;4(3):e001319.
doi: 10.1136/bmjgh-2018-001319. eCollection 2019.

Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal

Affiliations

Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal

Dharma N Bhatta et al. BMJ Glob Health. .

Abstract

Introduction: The advent of antiretroviral therapy (ART) has dramatically slowed down the progression of HIV. This study assesses the disparities in survival, life expectancy and determinants of survival among HIV-infected people receiving ART.

Methods: Using data from one of Nepal's largest population-based retrospective cohort studies (in Kathmandu, Nepal), we followed a total of 3191 HIV-infected people aged 15 years and older who received ART over the period of 2004-2015. We created abridged life tables with age-specific survival rates and life expectancy, stratified by sex, ethnicity, CD4 cell counts and the WHO-classified clinical stage at initiation of ART.

Results: HIV-infected people who initiated ART with a CD4 cell count of >200 cells/cm3 at 15 years had 27.4 (22.3 to 32.6) years of additional life. People at WHO-classified clinical stage I and 15 years of age who initiated ART had 23.1 (16.6 to 29.7) years of additional life. Life expectancy increased alongside the CD4 cell count and decreased as clinical stages progressed upward. The study cohort contributed 8484.8 person years, with an overall survival rate of 3.3 per 100 person years (95% CI 3.0 to 3.7).

Conclusions: There are disparities in survival among HIV-infected people in Nepal. The survival payback of ART is proven; however, late diagnosis or the health system as a whole will affect the control and treatment of the illness. This study offers evidence of the benefits of enrolling early in care in general and ART in particular.

Keywords: HAART; HIV; disparities; mortality; survival.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Kaplan-Meier survival estimate with 95% CI. ART, antiretroviral therapy.
Figure 2
Figure 2
Statistical comparison among survival curves. ART, antiretroviral therapy.

References

    1. Zwahlen M, Harris R, May M, et al. . Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009;38:1624–33. 10.1093/ije/dyp306 - DOI - PMC - PubMed
    1. Mills EJ, Bakanda C, Birungi J, et al. . Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011;155:209–16. 10.7326/0003-4819-155-4-201108160-00358 - DOI - PubMed
    1. May M, Gompels M, Delpech V, et al. . Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV cohort (UK chiC) study. BMJ 2011;343:d6016 10.1136/bmj.d6016 - DOI - PMC - PubMed
    1. Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 2008;372:293–9. 10.1016/S0140-6736(08)61113-7 - DOI - PMC - PubMed
    1. Croxford S, Kitching A, Desai S, et al. . Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. The Lancet Public Health 2016. - PubMed